BioLineRx files Form D for $3.75 million warrant-related offering

BioLineRx Ltd., based in Modi'in, Israel, filed a Form D notice with the SEC dated September 9, 2026, listing a date of first sale of August 27, 2026. The filing is marked as a New Notice with a date of first sale of 2026-08-27.¹

The offering combined registered and unregistered securities. The securities were issued in connection with an offering of 480,696 American depositary shares (ADSs) and 868,225 pre-funded warrants to purchase ADSs in a registered direct offering, and unregistered warrants to purchase 2,023,382 ADSs.¹ The total offering amount and total amount sold were both listed as $3,750,000, with $0 remaining to be sold.¹

The filing states the total number of investors who already invested in the offering was 1.¹ Sales compensation involved a placement agent. Chardan Capital Markets LLC, located at 1 Pennsylvania Plaza, Suite 4800, New York, was listed as a recipient of sales compensation, with solicitation in All States plus New York.¹ Sales commissions were estimated at $262,500, with no finders' fees.¹ The filing notes that Chardan is also entitled to 1.0% of gross proceeds as a management fee and $50,000 for accountable expenses.¹

Regarding use of proceeds, the company said it intends to use net proceeds for research and development activities and working capital and general corporate purposes.¹ The exemption claimed was under Rule 506(b), and the offering was not tied to a business combination transaction. The notice was signed by Chief Financial Officer Mali Zeevi on September 9, 2026.